Prostatic Neoplasms Clinical Trials

43 recruitingLast updated: June 17, 2026

There are 43 actively recruiting prostatic neoplasms clinical trials across 49 countries. Studies span Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4. Top locations include New York, New York, United States, Atlanta, Georgia, United States, Manchester, United Kingdom. Updated daily from ClinicalTrials.gov.


Prostatic Neoplasms Trials at a Glance

43 actively recruiting trials for prostatic neoplasms are listed on ClinicalTrialsFinder across 6 cities in 49 countries. The largest study group is Phase 1 with 13 trials, with the heaviest enrollment activity in New York, Atlanta, and Manchester. Lead sponsors running prostatic neoplasms studies include National Cancer Institute (NCI), Janssen Research & Development, LLC, and Merck Sharp & Dohme LLC.

Browse prostatic neoplasms trials by phase

Treatments under study

About Prostatic Neoplasms Clinical Trials

Looking for clinical trials for Prostatic Neoplasms? There are currently 34 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Prostatic Neoplasms trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Prostatic Neoplasms clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 43 trials

Recruiting

Men at High Genetic Risk for Prostate Cancer

Prostatic Neoplasms
National Cancer Institute (NCI)500 enrolled1 locationNCT03805919
Recruiting

Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

Prostate CancerProstatic Neoplasms
National Cancer Institute (NCI)300 enrolled1 locationNCT01834001
Recruiting
Phase 3

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled286 locationsNCT06925737
Recruiting

Collection of Blood From Patients With Prostate Cancer

Prostate CancerMetastatic Prostate CancerCancer of Prostate+2 more
National Cancer Institute (NCI)1,000 enrolled1 locationNCT00923221
Recruiting
Phase 3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled329 locationsNCT06136650
Recruiting
Phase 1

A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

Prostatic Neoplasms
Janssen Research & Development, LLC140 enrolled6 locationsNCT07082920
Recruiting
Phase 1

A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

Prostatic Neoplasms
Janssen Research & Development, LLC40 enrolled5 locationsNCT07319871
Recruiting
Phase 3

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC800 enrolled136 locationsNCT07225946
Recruiting
Phase 2

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Prostate CancerProstate AdenocarcinomaProstatic Neoplasms
National Cancer Institute (NCI)42 enrolled1 locationNCT05616650
Recruiting

A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France

Prostatic NeoplasmsMetastatic Hormone Sensitive Prostate Cancer
Janssen Cilag S.A.S.270 enrolled1 locationNCT07451002
Recruiting
Phase 1

A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer

Prostatic Neoplasms
Janssen Research & Development, LLC355 enrolled15 locationsNCT06095089
Recruiting
Phase 1Phase 2

Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)

Prostatic Neoplasms, Castration-Resistant
Merck Sharp & Dohme LLC220 enrolled77 locationsNCT06353386
Recruiting
Phase 3

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Prostate CancerProstatic Neoplasms
Clarity Pharmaceuticals Ltd383 enrolled31 locationsNCT06056830
Recruiting
Phase 1Phase 2

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection

Prostate CancerMetastatic Castration-resistant Prostate CancerUrogenital Neoplasms+3 more
Blue Earth Therapeutics Ltd82 enrolled21 locationsNCT05413850
Recruiting
Phase 1Phase 2

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

Prostatic Neoplasms, Castration-Resistant
Clarity Pharmaceuticals Ltd54 enrolled7 locationsNCT04868604
Recruiting
Not Applicable

Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.

Prostatic Neoplasms
University of Alicante66 enrolled1 locationNCT07572760
Recruiting

A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

Prostatic NeoplasmsMetastatic Hormone Sensitive Prostate Cancer
Bayer1,400 enrolled1 locationNCT07406282
Recruiting
Phase 1Phase 2

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)Prostatic Neoplasms, Castration-Resistant+3 more
Celcuity Inc54 enrolled13 locationsNCT06190899
Recruiting
Phase 2

Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance

Prostate CancerProstate AdenocarcinomaProstatic Neoplasms
Icahn School of Medicine at Mount Sinai120 enrolled1 locationNCT07285057
Recruiting
Not Applicable

Prostate Adaptive Radiation Therapy

Prostatic Neoplasms
Royal North Shore Hospital130 enrolled1 locationNCT06547398